Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma

Author:

Safdar Nida S1,Stasenko Marina23,Selenica Pier4,Martin Axel S5,da Silva Edaise M4,Sebastiao Ana Paula Martins46,Krystel-Whittemore Melissa14,Abu-Rustum Nadeem R2,Reis-Filho Jorge S4,Soslow Robert A4,Shen Ronglai5,Mueller Jennifer J2,Oliva Esther1,Weigelt Britta4ORCID

Affiliation:

1. Department of Pathology, Massachusetts General Hospital, Harvard Medical School , Boston, MA, USA

2. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA

3. Current affiliation: Department of Obstetrics and Gynecology, NYU Grossman School of Medicine , New York, NY, USA

4. Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA

5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY, USA

6. Current affiliation: Department of Medical Pathology, Federal University of Paraná , Curitiba, Paraná, Brazil

Abstract

Abstract Low-stage, low-grade endometrioid endometrial carcinoma (EEC), the most common histologic type of endometrial cancer, typically has a favorable prognosis. A subset of these cancers, however, displays an aggressive clinical course with early recurrences, including distant relapses. All statistical tests were 2-sided. Using a combination of whole-exome and targeted capture sequencing of 65 FIGO stage IA and IB grade 1 EECs treated with surgery alone, we demonstrate that chromosome 1q gain (odds ratio [OR] = 8.09, 95% confidence interval [CI] = 1.59 to 54.6; P = .02), PIK3CA mutation (OR = 9.16, 95% CI = 1.95 to 61.8; P = .01), and DNA mismatch repair-deficient molecular subtype (OR = 7.92, 95% CI = 1.44 to 87.6; P = .02) are independent predictors of early recurrences within 3 years in this patient population. Chromosome 1q gain was validated in an independent dataset of stage I grade 1 EECs subjected to whole-exome sequencing. Our findings expand on the repertoire of genomic parameters that should be considered in the evaluation of patients with low-stage, low-grade EEC.

Funder

NIH

NCI

Reis-Filho and B Weigelt

Breast Cancer Research Foundation

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3